Categories: News

GBS Inc. to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on August 11

– Company to Host Conference Call & Webcast at 4:30 p.m. ET –

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) — GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2021, shortly after the NASDAQ market close on Wednesday, August 11. Management will then host a conference call and webcast at 4:30 p.m. ET.

Title: GBS,Inc. Fourth Quarter 2021 and Full Year Financial Results
Conference Call & Webcast
   
Date: Wednesday, August 11, 2021    
Time: 4:30 p.m. ET    
Conference
Call Details:
Toll-Free: 877-407-3982
International: 201-493-6780
Conference ID: 13721414
   
The conference call will be webcast live from the Company’s website and will be available via the following links:  
Webcast: http://public.viavid.com/index.php?id=145701
https://investors.gbs.inc/news-and-events/investor-calendar
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.

About GBS Inc.
GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes.

For more information, please visit GBS.inc or follow GBS Inc. on Twitter and LinkedIn.        

Investor Contact:
LifeSci Advisors, LLC
Jeremy Feffer – Managing Director
212-915-2568
jeremy@lifesciadvisors.com

Company Contact:
The iQ Group Global
Alex Arzeno – VP Investor Relations
alex.arzeno@theiqgroupglobal.com

 

Staff

Recent Posts

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…

3 hours ago

Modular Medical Announces Pricing of $8.2 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…

6 hours ago

Nicole Garrett and Under Pressure Hyperbarics Lead the Charge in Wellness Education With Immersive Events at L.A. Fashion Weekend and Beyond

BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…

9 hours ago

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

12 hours ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

12 hours ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

12 hours ago